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Introduction: Angiogenesis is essential for tumor growth and 
adaptation to hypoxia of the tumor. Hypoxia inducible factor-
1alpha (HIF-1α), a major regulator of adaptation to hypoxic 
stress, facilitates tumoral angiogenesis, growth and aggressive 
tumoral behavior such as invasion or metastasis. HIF-1α 
overexpression relates with increase of disease mortality and 
resistance to chemo- or radiation therapy. Perfusion CT is one 
of feasible techniques to evaluate tumor vascularity and it 
provides regional maps and quantitative measurements of 
various hemodynamic parameters of tumors. Therefore, the 
purpose of this study was to investigate the relationship 
between perfusion CT parameters and HIF-1α expression in a 
VX2 tumor rabbit model. 
Methods: VX2 carcinoma tumors implanted in bilateral back 
muscle of 10 rabbits were evaluated with perfusion CT. Serial 
perfusion CT was performed on 7days, 10days and 14 days 
after tumor implantation. CT Perfusion data were analyzed to 
calculate blood flow (BF), blood volume (BV), and permeability 
of the whole tumor and the nonnecrotic peripheral area. These 
parameters were correlated with intratumoral HIF-1α 
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expression. For statistical analysis, Spearman rank correlation 
analysis and Mann-Whitney test were used. 
Results: A total of 20 tumors were analyzed for HIF-1α 
expression. HIF-1α was expressed in twelve tumors; 2, 3 and 
7 tumors were classified as score 1, 2 and 3. Five (5/6, 83.3%), 
4 (4/6, 66.7%) and 3 (3/8, 37.5%) tumors were obtained on 
days 7, 10, and 14 after tumor implantation. Permeability of the 
whole tumor showed significant positive correlation with HIF-
1α score (r = 0.45, p < 0.05). Permeability of the periphery 
showed more significant positive correlation with HIF-1α 
score (r = 0.89, p < 0.001). Permeability of HIF-1α positive 
group was significantly higher than HIF-1α negative group (p 
< 0.05; the whole tumor, p < 0.001; the periphery).  
Conclusions: In VX2 tumor, HIF-1α expression positively 
correlated with permeability from perfusion CT imaging and the 
correlation of the periphery was stronger than the whole tumor. 
Perfusion CT can be used as surrogate marker in the 
surveillance of HIF-1α activity. 
------------------------------------- 
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Angiogenesis is essential for tumor growth, invasion, and 
metastasis. If neovascularization is absent, tumors cannot grow 
because oxygen lack in the center of the tumor results in 
apoptosis and necrosis. Therefore, cancer cells have to adapt 
themselves to hypoxia by several mechanisms (1, 2). Hypoxia 
inducible factor-1 alpha (HIF-1α) is a major regulator of cell 
adaptation to hypoxic stress and plays a critical role in 
angiogenesis. It is the oxygen-regulated subunit of HIF-1 and 
determines HIF-1 activity (3). HIF-1α controls the 
expression of more than 40 target genes that play crucial roles 
in angiogenesis, tumoral growth, erythropoiesis and biological 
events associated with aggressive tumor behavior such as 
invasion or metastasis (4). Clinical data indicate that HIF-1α 
overexpression is associated with increased risk of patient 
mortality in many cancers (5). Furthermore, a growing number 
of HIF-1α inhibitors for cancer therapy are in clinical trials or 




Perfusion computed tomography (CT) is a feasible technique 
to evaluate tumor vascularity. It is on the basis of the linear 
relationship between CT enhancement and iodinated contrast 
material concentration. Perfusion CT provides regional maps 
and quantitative measurements of various hemodynamic 
parameters such as tumor angiogenesis, blood perfusion, and 
vascular permeability (6-10). With the relatively recent 
development of multi-detector CT (MDCT) performing 
volume-based technique and the release of commercially 
available software packages, the application of perfusion CT to 
the study of various organs have increased (8, 11-16). 
Especially, a number of studies introduced perfusion CT as a 
monitoring modality of antiangiogenic therapy for various 
tumors (e.g., brain tumor, renal cell carcinoma, hepatocellular 
carcinoma, gastrointestinal cancer and prostate cancer) (17-
21). Given that HIF-1α is critical for tumor angiogenesis, we 
hypothesized that perfusion parameters may be surrogate 
markers for expression of HIF-1α. 
Thus, the purpose of this study was to assess the relationship 
between dynamic contrast-enhanced perfusion CT parameters 
and HIF-1α expression in a VX2 tumor rabbit model. 
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MATERIALS AND METHODS 
1. Animal model  
This study was approved by the animal care committee at our 
institute. The rationale for selecting the VX2 tumor as the 
experimental model is as follows. The blood supply is similar to 
that of human hepatocellular carcinoma, the tumor grows 
rapidly, and the tumor becomes a relatively large tumor that is 
easily identified by imaging (22-24). Ten adult New Zealand 
white rabbits weighing 3.0 to 3.5 kg each were used. A 24-
gauge medicut was inserted into an auricular vein. Anesthesia 
was induced with intravenous ketamine hydrochloride (50 mg 
per kg of body weight; Ketamine, Yuhan, Korea) and 2% 
xylazine (0.1 mL/kg; Rompun, Bayer, Germany). The bilateral 
back parallel to spine of the rabbits was sterilized after shave 
and rabbits were positioned prone on the table. Under the 
ultrasound (US) guide, the 21-gauge Chiba needle was 
inserted into bilateral back muscle at the level of kidney. Then, 
a VX2 tumor suspension (0.1mL) was slowly injected into each 
back muscle through the Chiba needle. Finally, injection site 
marking was performed at the resultant 20 tumors for 
facilitation of tumor localization, 
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2. Perfusion CT examination 
One week following tumor implantation when the tumors were 
expected to be round in shape with a 1cm diameter, perfusion 
CT scanning was performed in all 10 rabbits. For 
histopathologic comparison at the intermediate time points of 7 
10 and 14 days after tumor implantation, three rabbits for each 
time point were sacrificed after CT imaging. Before CT 
scanning, anesthesia was induced as described above. Then, 
rabbits were fixed on a CT board in the supine position and a 
thoracoabdominal bandage was applied to reduce any movement 
artifacts. 
All perfusion CT imaging were performed with a 64–detector 
row dual-source scanner (Siemens Definition; Siemens Medical 
Solutions, Erlangen, Germany). To localize the tumor, a 
noncontrast CT study (80 kV; 120 mAs; detector configuration, 
20x0.6 mm; rotation time, 1 second; section thickness, 5.0 mm; 
reconstruction interval, 5.0 mm; reconstruction kernel, H31s) 
was performed for complete coverage of the tumor. The 
marking of the tumor injection site was a good guide to tumor 
localization. An experienced radiologist (J.I.K.) with three 
years of experience in chest perfusion CT analyzed the 
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unenhanced CT images and selected a fixed scanning range to 
cover the entire mass with care taken to avoid possible 
exclusion of the peripheral portion of the mass during free 
breathing. 
A total of 6.5mL of nonionic iodinated contrast medium 
(Ultravist 370, Schering, Berlin, Germany) was injected using 
dual-phase injection protocol (3 mL at 0.5 mL/sec and 3.5 mL 
at 0.1 mL/sec followed by a 1.5 mL saline flush at 0.1 mL/ sec) 
and a dual-head power injector (MedradStellant Dual; Medrad, 
Indianola, Pa). Perfusion CT imaging was performed 2 seconds 
after injection with free-breathing dynamic acquisition. CT 
parameters were as follows: 120 kV, 150 mAs; detector 
configuration, 24x1.2 mm; rotation time, 0.33 second; section 
thickness, 3.0 mm; reconstruction interval, 2 mm; 
reconstruction kernel, B20f. Dynamic CT scans were obtained 
40 times for each mass with a 1.5 second interval for the first 
20 scans, a 3 second interval for the 10 scans and a 6 second 
interval for the remaining 10 scans. Total scanning time was 
120 seconds. 
3. Quantification of perfusion parameters 
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All reconstructed image data were transferred to a 
commercially available imaging workstation (CT workplace; 
Siemens, Germany). An experienced radiologist (J.I.K.) 
performed the measurement of perfusion parameters using 
commercial software (Syngo VPCT, Siemens Healthcare, 
Forchheim, Germany). The measurement was performed with 
computerized motion correction using whole tumor coverage. 
For this measurement, an automated three-dimensional motion 
correction algorithm featuring a previously described nonrigid 
registration model was applied to the perfusion datasets (25). 
Motion-corrected images were then used to calculate the 
perfusion parameters. Arterial input was measured by placing a 
circular region of interest within the abdominal aorta and an 
arterial time-enhancement curve was automatically generated 
with the software (Figure 1A, B, Figure 2A-D). 
The volume of interest (VOI) of the whole tumor was drawn 
manually around the tumor outline in all three planes (axial, 
coronal, and sagittal) with exclusion of adjacent muscle (Figure 
1A). The following settings were adopted for segmentation: 
tissue upper and lower limits of 150 and -50 HU, respectively, 
reference vessel input window width and a center of 300 and 
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150 HU, respectively, and percentage of relative threshold 
inside and outside of 50 and 50, respectively. The VOI of whole 
tumor was 1.06 ± 0.85 (0.17-3.01cm3). 
The second measurement was performed using smaller VOIs. 
Four VOIs were drawn manually at the periphery of the tumor; 
ROI ranged from 0.01 to 0.06 cm3 with a mean value of 0.02 (± 
0.01); a central necrotic low attenuated lesion and adjacent 
muscle or subcutaneous tissue were avoided as far as possible 
(Figure 1B). The average value of four VOIs was taken as the 
value of “periphery” of the tumor. 
The quantification of perfusion parameters was performed 
forty-two times for 20 tumors (20 on days 7, 14 on days 10, 
and 8 on days 14 after tumor implantation). In each 
measurement of perfusion CT, blood flow (BF; ml/100 ml/min), 
blood volume (BV; ml/100 ml), and permeability (ml/100 
ml/min) were obtained. In the software (Syngo VPCT, Siemens 
Healthcare, Forchheim, Germany) of this study, blood flow was 
calculated using the maximum slope method (26) and blood 










Figure 1. Quantification of perfusion parameters; step I. 
Axial CT image shows VX2 tumors at bilateral back muscle. 
Circled areas in the tumors are volume of interest (VOI) (A) 
outlining visible tumor and (B) of the periphery. Four VOIs of 
the periphery were manually drawn on every tumor. Arrows 
indicates circular region of interest (ROI) of the abdominal 

















Figure 2. Quantification of perfusion parameters; step II. 
(A) Arterial time-enhancement curve of abdominal aorta. (B) 
Blood volume, (c) blood flow and (d) permeability parametric 
maps were obtained based on arterial time-enhancement curve.
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4. Histopathologic evaluation  
Immunohistochemical staining 
Every perfusion CT scanning was completed, a transverse line 
at the skin of the rabbits was marked where the CT images had 
been obtained. Sacrificed rabbits were euthanized with an 
intravenous injection of a lethal amount of sodium thiopental 
(Pentothal) and were frozen in are refrigerator at -70°C in 
the position used for CT imaging. More than 24 hours later, 
rabbits were cut in the axial plane according to the guidance of 
the transverse line marked on the skin with 5 mm thickness. 
After each slice of the specimens was fixed with 10% 
phosphate-buffered formaldehyde and embedded in paraffin, 
pathologic specimens (approximately 5 μm thick) were 
obtained. Paraffin sections were dewaxed and washed with 
hydrogen peroxide for 5minutes and then rinsed gently with 
instilled water. The slides were then blocked with protein at 
room temperature for 5 minutes. These sections were stained 
with mouse anti–HIF-1α IgG2b monoclonal antibody (NB100 –
123, Novus Biologicals, Littleton, Colorado; dilution, 1:40,000) 
for 15 minutes. After15 minutes, slides were washed with 
freshly prepared Tris-Buffered Saline solution with Tween 
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(TBST) three times for 3–5 minutes each. Slides were then 
incubated with a secondary anti-mouse immunoglobulin–HRP 
and then washed with TBST solution three times for 3–5 
minutes each (28). The sections were conterstained with 
hematoxylin and mounted. 
Assessment of immunohistochemical staining  
One pathologist (M.A.K.), who was blinded to the results of 
the perfusion CT scan, performed the histologic grading of 
HIF-1α. For evaluation of HIF-1α expression, at least five 
fields were randomly selected and a total of more than 1,000 
tumor cells were microscopically counted under high 
magnification (400 x). The nuclear staining of the HIF-1α was 
predominant at the invading edge of the tumor border and at the 
periphery of necrotic areas within tumors (29). The HIF-1α 
expression was defined as positive if nuclear staining was 
observed in ≥5% of the tumor cells. Simultaneous cytoplasmic 
staining was excepted because nuclear HIF-1α determines 
the functional activity of the HIF-1α complex (Fig 3A, B) 
(30). According to the percentage of tumor cells stained, four 
categories were applied for grading of the HIF-1α expression: 










Figure 3. Immunoreactivity for hypoxia-inducible factor-1 alpha 
(HIF-1α) (A, B; X400). 
HIF-1α is mainly identified as positive staining in the nucleus 
of cancer cells (arrowheads). Inflammatory cells adjacent to the 
cancer cells also express HIF-1α and they were excluded at 
scoring of HIF-1α expression (arrows); (A)A total of 24 from 
276 cancer cells express HIF-1α(slide from the tumor with 
score 2) and (B) a total of 43 from 208 cancer cells express 
HIF-1α (slide from the tumor with score 3).  
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5. Statistical analysis 
Statistical analysis was performed using SPSS version 18.0 
software for Windows (SPSS Inc., Chicago, IL). The data were 
reported as the mean ± standard deviation. The association 
between each of the three perfusion parameters and HIF-1α 
score evaluated on histologic specimen was estimated by using 
the Spearman correlation coefficient. The difference in the VOI 
between HIF-1α positive and negative tumors were tested for 
significance with the Mann-Whitney test. A two-tailed P value 
of less than 0.05 was considered a statistically significant 




On days 7, 10 and 14 after tumor implantation, the volume of 
whole tumor significantly increased as duration of tumor 
implantation increased; 0.31 ± 0.15, 0.78 ± 0.31 and 1.85 ± 
0.76 cm3, respectively. Table 1 summarizes mean value of 
serial CT perfusion parameters at each time points. Both of the 
whole tumor and the periphery, BF and permeability showed 
trend of increase and decrease, respectively, as duration of 
tumor implantation increased. Both of the whole tumor and the 
periphery, difference of BV between each time points was 
diminutive. When perfusion parameters of the whole tumor 
were compared with that of the periphery, BV of the whole 
tumor was significantly higher than the periphery (p < 0.001; 
paired t-test). BF of the whole tumor was slightly higher than 




Table 1. Perfusion parameters and tumor volume of the whole tumor and periphery at each time point 
 
 
Whole Tumor  Periphery 
















8.73±4.19 8.79±4.67 5.92±1.00  9.66±1.76 6.89±1.55 7.00±2.63 
 
 





A total of twenty VX2 tumors were analyzed for HIF-1α 
expression using immunohistochemical staining; 6, 6 and 8 
tumors were obtained on days 7, 10 and 14 after tumor 
implantation, respectively. HIF-1α was expressed in twelve 
tumors; 2, 3 and 7 tumors were classified as score 1, 2 and 3. 
Among HIF-1α positive tumors, 5 (5/6, 83.3%), 4 (4/6, 
66.7%) and 3 (3/8, 37.5%) tumors were obtained on days 7, 10, 
and 14 after tumor implantation, respectively. HIF-1α 
expression decreased as the time after tumor implantation 
elapsed with not enough statistical significance (p = 0.08). 
Correlation between HIF-1α Expression and Perfusion 
Parameters 
Table 2 summarizes mean value of CT perfusion parameters 
according to the HIF-1α score. In the measurement of the 
whole tumor, there was statistically significant positive 
correlation between HIF-1α score and permeability (r = 0.45, 
p < 0.05). In measurement of the periphery, there was more 
significant positive correlation between HIF-1α score and 
permeability (r = 0.89, p < 0.001) (Fig. 4A). BF and BV 
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showed not considerable negative correlation with HIF-1α 
score (r = -0.04, p = 0.87, r = -0.21, p = 0.38, respectively; 
the whole tumor, r = -0.05, p = 0.84, r = -0.20, p = 0.39, 
respectively; the periphery). 
In the HIF-1α positive group (n=12), BF, BV and 
permeability of the whole tumor was 50.14 ± 17.81, 16.20 ± 
4.54, and 8.14 ± 3.25, respectively; BF, BV and permeability 
of the periphery was 57.40 ± 21.80, 19.23 ± 4.46, and 8.96 
± 1.36, respectively. In the HIF-1α negative group (n=8), 
BF, BV and permeability of the whole tumor was 48.79 ± 
16.04, 16.04 ± 3.92, and 5.88 ± 1.01, respectively; BF, BV 
and permeability of the periphery was 59.74 ± 17.83, 19.87 
± 3.40, and 5.92 ± 0.84, respectively (Fig. 4B). Permeability 
of the HIF-1α positive group was significantly higher than the 
HIF-1α negative group (p < 0.05; the whole tumor, P < 0.001; 
the periphery). There was no significant difference of VOI 
between HIF-1α positive and negative group (p = 0.24; 0.87 
± 0.77, 1.35 ± 0.93, respectively). 
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Table 2. Perfusion parameters of the whole tumor and periphery according to HIF-1α score 
 Whole Tumor 
HIF-1α score 0 (n=8) 1 (n=2) 2 (n=3) 3 (n=7) P 
 Blood flow (ml/100ml/min) 48.78±16.03 63.86±23.56 29.81±8.45 54.94±12.99 0.87 
 Blood volume (ml/100ml) 16.04±3.91 20.7±3.18 18.63±4.92 13.88±3.47 0.37 
  Permeability (ml/100ml/min) 5.88±1.01 6.46±0.03 7.90±1.28 8.72±4.17 
< 0.05  
(r= 0.45) 
 Periphery 
HIF-1α score 0 (n=8) 1 (n=2) 2 (n=3) 3 (n=7) P 
 Blood flow (ml/100ml/min) 59.74±17.83 81.05±28.36 34.94±10.48 60.27±15.88 0.84 
 Blood volume (ml/100ml) 19.87±3.40 22.19±1.28 20.35±5.42 17.90±4.57 0.39 
  Permeability (ml/100ml/min) 5.92±0.84 7.43±0.81 8.53±0.64 9.59±1.34 






Note. Data are presented as mean ± standard deviation.  









Figure 4. Correlation of HIF-1α expression and perfusion 
parameters 
(A) Permeability shows significant positive correlation with 
HIF-1α score by using a Spearman rank correlation. The 
correlation of HIF-1α score and permeability of the periphery 
is stronger than the whole tumor(r = 0.89, p < 0.001 vs. r = 
0.45, p < 0.05, respectively). Error bars = standard deviation 
(B) BF and BV between HIF-1αpositive (+) and negative (-) 
group are not substantially different. Permeability of the HIF-
1α (+) group was significantly higher than the HIF-1α 





Tumor angiogenesis is the system of organization of 
supplementary blood vessels from the preexisting ones. With 
the development of anti-angiogenic drugs that target inhibition 
of tumor angiogenesis, techniques that evaluate tumor 
angiogenesis have emphasized clinical practice. Intratumoral 
changes after this kind of treatment are important to recognize 
because in contrast to other anticancer therapies, such as use 
of cytotoxic agents and irradiation, a decrease in tumor volume 
is not an expected treatment response (31). There are several 
requisites for an optimal imaging technique to monitor therapy 
response: The method should be noninvasive and quantitative, 
sample the entire tumor, be quick to perform, and allow 
repetition at frequent interval (32). The perfusion CT has 
showed its possibility as a practical imaging modality to 
evaluate tumor vascularization. 
HIF-1α activity in regions of intratumoral hypoxia mediates 
angiogenesis, epithelial-mesenchymal transition, stem-cell 
maintenance, invasion, metastasis, and resistance to radiation 
therapy and chemotherapy (5). A growing number of drugs 
have been identified that inhibit HIF activity by a variety of 
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molecular mechanisms and the clinical significant HIF -1α has 
highlighted for increase of the survival of cancer patient. 
Previous study showed that correlation of perfusion CT 
parameters and expression of microvessel density (MVD) or 
vascular endothelial growth factor (VEGF) in various tumors (5, 
24, 33-35). In this study, we investigated the feasibility of 
perfusion CT as a noninvasive modality predicting HIF-1α 
expression in a VX2 tumor model. 
Previous studies reported that there was no significant 
correlation between HIF-1α expression and tumor size (36-
39). In this study, there was no statistically significant 
deference in volume of whole tumor between HIF-1α negative 
and positive group, suggesting poor effect of tumor size in 
expression of HIF-1α(p = 0.24). It can explain why the size 
of tumor cannot reflect the status of tumor perfusion or HIF-
1α expression and why the perfusion parameters can be a 
more sensitive marker for anti-angiogenic therapy. 
In this study, permeability increased in proportion to HIF-Iα 
expression and the correlation of the periphery was more 
significant than the whole tumor (Figure 4A). Moreover, 
permeability was significantly higher in HIF-1α positive group 
29 
 
than in HIF-1α negative group and the difference of the 
periphery were also more significant than the whole tumor. In 
the hypoxic condition, angiogenesis is activated at the edge of 
the tumor while the center progress tumor necrosis. This 
feature can explain predominant nuclear staining of the HIF-
1α at periphery of tumor and stronger correlation with HIF-
1α or more significant difference in permeability of the 
periphery between HIF-1α positive and negative group. 
Therefore, the perfusion parameters of the periphery relevantly 
reflected status of the tumor perfusion, although interobserver 
and intraobserver agreement of the periphery was poor than 
the whole tumor because of VOI size (40). For reduction of 
poor interobserver and intraobserver agreement of the 
periphery, this study used mean values of four VOIs in 
calculating perfusion parameters of the periphery. 
There were some limitations in our study. First, we did not 
use any intervention developing direct tumor hypoxia. We 
assumed that tumor growth in itself caused tissue hypoxia and 
this study was performed under this hypothesis. The results of 
this study, no use of anti-angiogenic drug, is insufficient to 
apply at hypoxia resulted from antiangiogenic drug. Second, we 
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identified relationship between HIF-1α expression and 
perfusion parameters except for survey about prognostic effect 
of these relationships. However, we hope to this study can be a 
cornerstone that correlate perfusion parameter with HIF-1α 
expression in terms of anti-angiogenic treatment.  
In conclusion, HIF-1α expression is related with increase of 
permeability and perfusion parameters can provide appropriate 
information about tissue perfusion. We hope that perfusion 
parameters can be a new surrogate marker of HIF-1α 
expression and can be a parameter predicting treatment 
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국   
 
:  종양  신생  생  종양  장  hypoxia 에 한 종
양  에 요한 역할  한다. Hypoxia inducible factor-
1alpha (HIF-1α)는 hypoxic stress 에 한 주요 regulator  
종양  생   이나 침 과 같  종양  공격  용이하게 
한다. HIF-1α 과  항암 료나 사 료  항  증가  
자  mortality 증가  이 높다.  
Perfusion CT 는 종양  vascularity 평가에 용한 법  하
나  다양한 액역학 지수(blood volume (BV), blood flow (BF), 
permeability)들  객  산출할 수 있어 antiangigenic 료
 monitoring modality 도 주목 고 있다.  
Antiangiogenic 료  target 인 종양  생 에는 HIF-1α
가 결 인 역할  하며 재 HIF-1α에 한 연구는 히 진
행 고 있 며 HIF-1α  임상  요  커 가고 있다. 이 연
구에 는 토끼  VX2 tumor 모델에  HIF-1α 도  
perfusion CT 지수 변  상 계 여부를 연구하고자 하 다. 
법: 
연구자는 토끼  양  등에 VX2 tumor 를 이식한 후 7,10,14 일
째 는 날 perfusion CT 를 하 다. 종양 장에 른 HIF-1
α  도를 인하  해 perfusion CT  후 각각  마리
41 
 
 토끼를 sacrifice 하 다. Perfusion CT 후 체 종양  종
양  가장자리에  BV, BF, permeability 값  계산하여 얻었다.  
20 개  tumor specimen 에 하여 HIF-1α stain  하고 HIF-
1α  4 단계  나 었고 HIF-1α score 에 른 perfusion 
CT 지수들  변 에 한 상 계를 분 하 다.  
결과: 20개  종양   12개  종양에  HIF-1α  
인하 고, 2,3, and 7개  종양이 각각 score 1, score 2 and 
score 3  판 었다. 이  5 (5/6, 83.3%), 4 (4/6, 66.7%) and 
3 (3/8, 37.5%)개  종양  각각 종양 이식 후 7,10, 14일에 얻  
종양이었다. Permeability는 HIF-1α  양  상 계를 보이며 
periphery에  얻  값이 whole tumor보다  미 있는 
상 계를 보 다 (r = 0.45, p < 0.05; the whole tumor, r = 
0.89, p < 0.001: the periphery). HIF-1α양  종양  
permeability가 HIF-1α  종양보다 하게 높 며 
periphery에  얻  값이 좀  한 차이를 보 다 (p < 0.05; 
the whole tumor, P < 0.001; the periphery).                                                                                                                              
결 : 결  HIF-1α  perfusion CT상 
permeability  양  상 계를 보이며 이러한 상  
periphery에  얻  값이  하다. 본 실험  통해 perfusion 
CT가 HIF-1α activity 평가에 있어 surrogate marker가  수 
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